Sun Pharma Acquires Organon to Enhance Presence in China
Sun Pharmaceutical Industries to Acquire Organon & Co in $11.75 Billion Deal
Sun Pharmaceutical Industries, India's largest drugmaker by market value, has announced its plans to acquire US-based drugmaker Organon & Co in an all-cash deal worth approximately $11.75 billion, including debt. This acquisition marks the largest overseas deal by an Indian pharmaceutical company, positioning Sun Pharmaceutical Industries as a significant player in the global market.
The acquisition is part of Sun Pharmaceutical Industries' strategy to expand its presence in higher-margin specialty medicines, specifically in areas such as dermatology, oncology, and obesity. The company aims to offset declining US sales through this move. By acquiring Organon & Co, Sun Pharmaceutical Industries will gain access to a portfolio of more than 70 women's health and general medicines sold across approximately 140 countries, adding global scale and a steady cash-generating business to its specialty pipeline.
Key Financial Figures
| Company | Market Value | Debt (Dec 31, 2025) | Profit (Dec 31, 2025) |
|---|---|---|---|
| Sun Pharmaceutical Industries | Over $40 billion | $198.4 million | $1.16 billion |
| Organon & Co | Not specified | $8.6 billion | Not specified |
Sun Pharmaceutical Industries will pay $14.00 per share for Organon & Co, representing a premium of over 24% to the April 24 closing price. The acquisition is expected to strengthen Sun's women's health portfolio and mark its entry into biosimilars. Organon & Co will also provide Sun Pharmaceutical Industries with access to emerging markets such as China, Brazil, and South Korea, helping the company scale up as a branded and specialty drugs player.
The acquisition is expected to be completed within 8-9 months, with Sun Pharmaceutical Industries planning to fund the deal through a combination of cash and committed bank financing. Organon & Co carries net debt of approximately $8.6 billion as of December 31, 2025, which will be integrated into Sun Pharmaceutical Industries' balance sheet. The company is confident that it will be able to accelerate repayment of debt, with Organon & Co's current debt expected to be swapped in the future.
With a strong balance sheet, debt concerns are expected to ease by the third year, positioning Sun Pharmaceutical Industries as a more dominant player by decade's end. The acquisition is expected to be EPS accretive from the start, providing a boost to Sun Pharmaceutical Industries' earnings.
Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data
Investor Takeaway
Sun Pharma's acquisition of Organon may enhance its presence in China and other emerging markets, but its impact on earnings is uncertain.
More in Market
SpaceX Seeks Record $75 Billion IPO, Potentially Positioning Elon Musk as the World's First Trillionaire
Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data
US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline
